SYT4

Across TCGA pan-cancer cohorts, SYT4 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SYT4 data layer compared with 20 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher SYT4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SYT4 expression acts as an unfavorable survival marker.

BLCA, STAD, and LUSC are the cancer types where SYT4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.206	0.623	.001	33	view →
STAD	OS	Median	All	0.168	0.621	.003	27	view →
LUSC	OS	Median	II,III,IV	0.179	0.687	.004	15	view →
LIHC	OS	Median	III,IV	0.118	0.615	.003	12	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SYT4–BLCA (OS)

Open the BLCA breakdown →